Literature DB >> 12930899

Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.

Ekaterina Dadachova1, Antonio Nakouzi, Ruth A Bryan, Arturo Casadevall.   

Abstract

There is an urgent need for new antimicrobial therapies to combat drug resistance, new pathogens, and the relative inefficacy of current therapy in compromised hosts. Ionizing radiation can kill microorganisms quickly and efficiently, but this modality has not been exploited as a therapeutic antimicrobial strategy. We have developed methods to target ionizing radiation to a fungal cell by labeling a specific mAb with the therapeutic radioisotopes Rhenium-188 and Bismuth-213. Radiolabeled antibody killed cells of human pathogenic fungus Cryptococcus neoformans in vitro, thus converting an antibody with no inherent antifungal activity into a microbicidal molecule. Administration of radiolabeled antibody to mice with C. neoformans infection delivered 213Bi and 188Re to the sites of infection, reduced their organ fungal burden, and significantly prolonged their survival without apparent toxicity. This study establishes the principle that targeted radiation can be used for the therapy of an infectious disease, and suggests that it may have wide applicability as an antimicrobial strategy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930899      PMCID: PMC196907          DOI: 10.1073/pnas.1731272100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  The role of tin in the direct labelling of proteins with Rhenium-188.

Authors:  E Dadachova; S Mirzadeh
Journal:  Nucl Med Biol       Date:  1997-08       Impact factor: 2.408

2.  Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection.

Authors:  J Rivera; M Feldmesser; M Cammer; A Casadevall
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

3.  High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Authors:  T M Behr; M Béhé; M G Stabin; E Wehrmann; C Apostolidis; R Molinet; F Strutz; A Fayyazi; E Wieland; S Gratz; L Koch; D M Goldenberg; W Becker
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

4.  Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype.

Authors:  N Lendvai; A Casadevall
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  188Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake.

Authors:  E Dadachova; J Chapman
Journal:  Nucl Med Commun       Date:  1998-02       Impact factor: 1.690

6.  Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.

Authors:  R M Sharkey; R D Blumenthal; T M Behr; G Y Wong; L Haywood; D Forman; G L Griffiths; D M Goldenberg
Journal:  Int J Cancer       Date:  1997-07-29       Impact factor: 7.396

7.  Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.

Authors:  J Y Wong; G E Thomas; D Yamauchi; L E Williams; T L Odom-Maryon; A Liu; J M Esteban; M Neumaier; S Dresse; A M Wu; F J Primus; J E Shively; A A Raubitschek
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

8.  Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.

Authors:  M Feldmesser; A Casadevall
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

9.  Cryptococcus neoformans meningitis in the rat.

Authors:  D L Goldman; A Casadevall; Y Cho; S C Lee
Journal:  Lab Invest       Date:  1996-12       Impact factor: 5.662

10.  Vascular targeted radioimmunotherapy with 213Bi--an alpha-particle emitter.

Authors:  S J Kennel; S Mirzadeh
Journal:  Nucl Med Biol       Date:  1998-04       Impact factor: 2.408

View more
  40 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

2.  Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice.

Authors:  Zewei Jiang; Ruth A Bryan; Alfred Morgenstern; Frank Bruchertseifer; Arturo Casadevall; Ekaterina Dadachova
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

3.  Antibody-guided alpha radiation effectively damages fungal biofilms.

Authors:  L R Martinez; R A Bryan; C Apostolidis; A Morgenstern; A Casadevall; E Dadachova
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells.

Authors:  Ruth A Bryan; Zewei Jiang; Xianchun Huang; Alfred Morgenstern; Frank Bruchertseifer; Rani Sellers; Arturo Casadevall; Ekaterina Dadachova
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

5.  Radioimmunotherapy of Cryptococcus neoformans spares bystander mammalian cells.

Authors:  Ruth A Bryan; Zewei Jiang; Alfred Morgenstern; Frank Bruchertseifer; Arturo Casadevall; Ekaterina Dadachova
Journal:  Future Microbiol       Date:  2013-09       Impact factor: 3.165

6.  Radiofungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans.

Authors:  Ruth A Bryan; Xianchun Huang; Alfred Morgenstern; Frank Bruchertseifer; Arturo Casadevall; Ekaterina Dadachova
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 7.  Fungal vaccines and immunotherapeutics.

Authors:  Evelyn Santos; Stuart M Levitz
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 8.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

Review 9.  Radioimmunotherapy of infectious diseases.

Authors:  Ekaterina Dadachova; Arturo Casadevall
Journal:  Semin Nucl Med       Date:  2009-03       Impact factor: 4.446

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.